Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764017130 |
Dexilant 30mg 30ct |
01/03/2019 |
8.22 |
282.46 |
03/05/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764017530 |
Dexilant 60mg 30ct |
01/03/2019 |
8.22 |
282.46 |
03/05/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764017590 |
Dexilant 60mg 90ct |
01/03/2019 |
24.68 |
847.39 |
03/05/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764030020 |
Entyvio 300mg 20mL Vial |
01/04/2019 |
182.92 |
6280.49 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
09/30/2019 |
64764030020 |
Entyvio 300mg 20mL Vial |
07/03/2019 |
188.41 |
6468.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product was not acquired from another company.
Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764080510 |
Rozerem 8mg 100ct |
01/03/2019 |
37.76 |
1296.74 |
11/16/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764080530 |
Rozerem 8mg 30ct |
01/03/2019 |
11.33 |
389.03 |
11/16/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764073030 |
Trintellix 10mg 30ct |
01/03/2019 |
5.67 |
383.67 |
03/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764075030 |
Trintellix 20mg 30ct |
01/03/2019 |
5.67 |
383.67 |
03/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764072030 |
Trintellix 5mg 30ct |
01/03/2019 |
5.67 |
383.67 |
03/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764091830 |
Uloric 40mg 30ct |
01/03/2019 |
9.63 |
330.03 |
09/08/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
03/31/2019 |
64764067730 |
Uloric 80mg 30ct |
01/03/2019 |
9.63 |
330.03 |
09/08/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459051230 |
ACTIQ 1200MCG |
01/01/2019 |
422.10 |
4913.00 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459051630 |
ACTIQ 1600MCG |
01/01/2019 |
520.80 |
6060.80 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459050230 |
ACTIQ 200MCG |
01/01/2019 |
176.90 |
2058.60 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459050430 |
ACTIQ 400MCG |
01/01/2019 |
223.90 |
2605.50 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459050630 |
ACTIQ 600MCG |
01/01/2019 |
274.40 |
3193.20 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459050830 |
ACTIQ 800MCG |
01/01/2019 |
324.80 |
3779.70 |
09/05/2006 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844011001 |
ADDERALL 10MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844011201 |
ADDERALL 12.5MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844011501 |
ADDERALL 15MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844012001 |
ADDERALL 20MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844013001 |
ADDERALL 30MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844010501 |
ADDERALL 5MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844011701 |
ADDERALL 7.5MG 100 |
01/01/2019 |
60.50 |
703.60 |
01/06/2021 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459070060 |
AMRIX 15 MG |
01/01/2019 |
204.80 |
2383.00 |
02/26/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459070160 |
AMRIX 30 MG |
01/01/2019 |
204.80 |
2383.00 |
02/26/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285052302 |
ANTABUSE 250MG 100 |
01/01/2019 |
70.80 |
824.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285052402 |
ANTABUSE 500MG 100 |
01/01/2019 |
113.30 |
1318.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285042410 |
AYGESTIN 5MG 50 |
01/01/2019 |
20.50 |
238.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
68546014256 |
AZILECT 0.5MG 30 |
01/01/2019 |
67.20 |
782.50 |
08/27/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
68546022956 |
AZILECT 1MG 30 |
01/01/2019 |
67.20 |
782.50 |
08/27/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
06/30/2019 |
00591280560 |
CLARITHROMYCIN 500MG ER TABLETS 60 |
04/10/2019 |
204.35 |
429.64 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
None |
Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price. |
225.29 |
225.29 |
2014 |
225.29 |
None |
Teva temporarily discontinued this product on July 23, 2018, and reintroduced it on April 10, 2019. |
Rx0000019 |
Teva Pharmaceuticals USA |
06/30/2019 |
00703505103 |
DESMOPRESSIN ACETATE INJ 4MCG/ML 10X1ML |
06/06/2019 |
536.20 |
595.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the past 5 years.
Also, Teva stopped selling this product in January 2012. Teva re-launched the product in June 2019. Given that the product was off the market for nearly 7.5 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution. |
Rx0000019 |
Teva Pharmaceuticals USA |
06/30/2019 |
00703505401 |
DESMOPRESSIN ACETATE INJ 4MCG/ML 1X10ML |
06/06/2019 |
536.20 |
595.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the past 5 years.
Also, Teva stopped selling this product in January 2012. Teva re-launched the product in June 2019. Given that the product was off the market for nearly 7.5 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution. |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459054128 |
FENTORA 100MCG |
01/01/2019 |
129.50 |
1506.90 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459054228 |
FENTORA 200MCG |
01/01/2019 |
163.60 |
1903.90 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459054428 |
FENTORA 400MCG |
01/01/2019 |
237.40 |
2762.40 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459054628 |
FENTORA 600MCG |
01/01/2019 |
308.20 |
3586.40 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459054828 |
FENTORA 800MCG |
01/01/2019 |
379.65 |
4418.30 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
52544008001 |
FIORICET 50/300/40MG 100 |
01/01/2019 |
44.00 |
512.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
1 |
"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price." |
449.93 |
None |
2013 |
227.00 |
None |
"No patent expiration date listed - no patents ever listed" |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
52544008201 |
FIORICET/CODEINE 50/300/40/30MG 100 |
01/01/2019 |
92.10 |
1071.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
1 |
"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price." |
942.09 |
None |
2013 |
475.00 |
None |
"No patent expiration date listed - no patents ever listed" |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459041230 |
GABITRIL 12MG |
01/01/2019 |
31.20 |
362.70 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459041630 |
GABITRIL 16MG |
01/01/2019 |
40.80 |
474.90 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459040230 |
GABITRIL 2MG |
01/01/2019 |
24.10 |
280.50 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459040430 |
GABITRIL 4MG |
01/01/2019 |
24.10 |
280.50 |
06/10/2017 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844021552 |
GALZIN 25MG 250 |
01/01/2019 |
35.00 |
407.30 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
57844020852 |
GALZIN 50MG 250 |
01/01/2019 |
58.30 |
678.80 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285013197 |
LOESTRIN 21 1.0MG/20MCG 105 |
01/01/2019 |
56.80 |
661.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285012797 |
LOESTRIN 21 1.5MG/30MCG 105 |
01/01/2019 |
56.80 |
661.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285012870 |
LOESTRIN FE 28 1.5MG/30MCG 140 |
01/01/2019 |
56.80 |
661.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285012570 |
LOESTRIN FE 28 1MG/20MCG 140 |
01/01/2019 |
56.80 |
661.30 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285009287 |
LOSEASONIQUE 182 |
01/01/2019 |
66.10 |
769.00 |
12/05/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285012058 |
MIRCETTE 28 .15MG/.02MG .01MG |
01/01/2019 |
71.20 |
828.50 |
10/20/2008 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459021530 |
NUVIGIL 150MG |
01/01/2019 |
68.40 |
795.90 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459022030 |
NUVIGIL 200MG |
01/01/2019 |
68.40 |
795.90 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Teva developed and launched the drug." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459022530 |
NUVIGIL 250MG |
01/01/2019 |
68.40 |
795.90 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459020530 |
NUVIGIL 50MG |
01/01/2019 |
22.70 |
264.50 |
06/18/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285006390 |
PREFEST 180 |
01/01/2019 |
72.50 |
844.00 |
03/20/2020 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
59310057922 |
PROAIR INH AERO 90MCG 1INH 200 |
01/01/2019 |
5.36 |
64.93 |
05/18/2031 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition.” |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
59310058020 |
PROAIR RESPICLICK 200 DOSE-117 |
01/01/2019 |
4.50 |
60.70 |
08/28/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition.” |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
00575620030 |
PROGLYCEM 50MG/ML 30ML |
01/01/2019 |
27.80 |
323.70 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed; CMS Market Date is defaulted to 1990." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459010130 |
PROVIGIL 100MG |
01/01/2019 |
95.70 |
1113.70 |
05/29/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
63459020130 |
PROVIGIL 200MG |
01/01/2019 |
144.60 |
1682.80 |
05/29/2024 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
59310020606 |
QNASL AERO 4.9GM 60 |
01/01/2019 |
18.87 |
228.55 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
59310021012 |
QNASL AERO 80MCG 8.7GM 120 |
01/01/2019 |
18.87 |
228.55 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285043187 |
QUARTETTE 182 |
01/01/2019 |
79.10 |
920.90 |
03/11/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285008787 |
SEASONIQUE 182 |
01/01/2019 |
66.10 |
769.00 |
12/05/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285055402 |
SURMONTIL 100MG 100 |
01/01/2019 |
101.90 |
1185.70 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285053802 |
SURMONTIL 25MG 100 |
01/01/2019 |
44.20 |
514.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285053902 |
SURMONTIL 50MG 100 |
01/01/2019 |
72.30 |
841.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285036801 |
TREXALL 10MG |
01/01/2019 |
78.00 |
908.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285036901 |
TREXALL 15MG |
01/01/2019 |
117.00 |
1362.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285036601 |
TREXALL 5MG |
01/01/2019 |
39.00 |
454.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285036701 |
TREXALL 7.5MG |
01/01/2019 |
58.50 |
681.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285004001 |
ZIAC 10MG/6.25MG 30 |
01/01/2019 |
16.70 |
194.00 |
03/24/2000 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285004702 |
ZIAC 2.5MG/6.25MG 100 |
01/01/2019 |
55.55 |
646.40 |
03/24/2000 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2019 |
51285005002 |
ZIAC 5MG/6.25MG 100 |
01/01/2019 |
55.55 |
646.40 |
03/24/2000 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"The drug was not acquired within the last 5 years." |
Rx0000134 |
Therakos, Inc. |
03/31/2019 |
64067021601 |
UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML |
01/01/2019 |
29.00 |
470.00 |
07/30/2008 |
Single Source Drug |
None |
1 |
Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. |
None |
The current price increase for Uvadex is not necessitated by a change or improvement. Please see the Cost Increase Factors field for the larger principles set forth in our pledge. |
None |
09/28/2015 |
The Gores Group |
None |
1 |
None |
360.00 |
300.00 |
2008 |
95.00 |
None |
None |
Rx0000057 |
Theratechnologies Inc. |
06/30/2019 |
62064001160 |
Tesamorelin Acetate 1 MG Solution Reconstituted 1 EA UD |
04/08/2019 |
425.00 |
5300.00 |
05/26/2020 |
Single Source Drug |
None |
1 |
None |
1 |
Recent research has demonstrated a decrease in liver fat, which is an important health concern for patients living with HIV and lipohypertrophy On-going studies to assess the impact of Egrifta on people living with HIV and mild cognitive impairment |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by Theratechnologies Inc. |